NEW YORK ( TheStreet) -- Oncothyreon (Nasdaq: ONTY) is trading at unusually high volume Thursday with 3.1 million shares changing hands. It is currently at four times its average daily volume and trading down 20 cents (-4.6%) at $4.15 as of 12:40 p.m. ET. Oncothyreon has a market cap of $269.8 million and is part of the health care sector and drugs industry. Shares are down 42.6% year to date as of the close of trading on Wednesday. Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for the treatment of cancer. Its primary product candidate, Stimuvax is in Phase III clinical trials for the treatment of non-small cell lung cancer. TheStreet Ratings rates Oncothyreon as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and poor profit margins. You can view the full Oncothyreon Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. Interested in other stocks that are falling on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVDOWN to 95370 or select from multiple alert options.